DocDollars

Progenics Pharmaceuticals, Inc.

MA · United States · Reporting entity ID 100000506815

Total reported 2019–2025
$25.7M
#272 of 2,960 reporting companies — 0% of all reported industry payments
$7.06M in general payments across 24,224 records, plus $18.6M in research funding across 1,800 records.

How it breaks down

General payments $7,056,567
Research funding $18,626,838

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Progenics Pharmaceuticals, Inc. reported $25.7M to US doctors and teaching hospitals from 2019 to 2025, ranking #272 of 2,960 reporting companies. 73% of that was research funding and 27% general payments such as consulting, speaking, food and travel. 24,224 general payment records and 1,800 research records were filed.

Common questions about Progenics Pharmaceuticals, Inc.

How much has Progenics Pharmaceuticals, Inc. paid US doctors?

Progenics Pharmaceuticals, Inc. reported $25,683,405 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $7,056,567 in general payments, $18,626,838 in research funding.

How does Progenics Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #272 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Progenics Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.